DOCSLIB.ORG

Nutrition | Conference Update: ICAAC and IDSA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

NutritioN | CoNference update: iCAAC aNd IDSa J a n u a r y + f ebruary 2012 Living on A PrAyer Can faith help sustain us when living with HIV? The hIV TreaTmenT & healTh Journal of TPAN COMPLERA is a prescription medicine used as a complete single-tablet regimen to treat HIV-1 in adults who have never taken HIV medicines before. COMPLERA does not cure HIV or AIDS or help prevent passing HIV to others. one The for me New COMPLERA A complete HIV treatment in only 1 pill a day. Ask your healthcare provider if it’s the one for you. Patient model. Pill shown is not actual size. INDICAINDICATIONTION DoDo not not take take COMPLERA COMPLERA if if you you are are taking taking the the following following medicines: medicines: BeforeBefore taking taking COMPLERA, COMPLERA, tell tell your your healthcare healthcare provider provider if if you: you: CommonCommon side side effects effects associated associated with with COMPLERA: COMPLERA: • •other other HIV HIV medicines medicines (COMPLERA (COMPLERA provides provides a a complete complete treatment treatment for for HIV HIV infection.) infection.) • •have have liver liver problems, problems, including including hepatitis hepatitis B B or or C C virus virus infection infection • • trouble trouble sleeping sleeping (insomnia), (insomnia), abnormal abnormal dreams, dreams, headache, headache, dizziness, dizziness, diarrhea, diarrhea, COMPLERACOMPLERA®® (emtricitabine (emtricitabine 200 200 mg/rilpivirine mg/rilpivirine 25 25 mg/tenofovir mg/tenofovir disoproxil disoproxil fumarate fumarate • • the the anti-seizure anti-seizure medicines medicines carbamazepine carbamazepine (Carbatrol (Carbatrol®®, Equetro, Equetro®®, T, egretolTegretol®®, , • •have have kidney kidney problems problems nausea,nausea, rash, rash, tiredness, tiredness, and and depression depression 300300 mg) mg) is is a a prescription prescription HIV HIV medicine medicine that that contains contains 3 3 medicines, medicines, EMTRIV EMTRIVAA®® Tegretol-XRTegretol-XR®®, T, erilTeril®®, Epitol, Epitol®®),), oxcarbazepine oxcarbazepine (T (Trileptalrileptal®®),), phenobarbital phenobarbital (Luminal (Luminal®®),), • •have have ever ever had had a a mental mental health health problem problem (emtricitabine),(emtricitabine), EDURANT EDURANT™™ (rilpivirine), (rilpivirine), and and VIREAD VIREAD®® (tenofovir (tenofovir disoproxil disoproxil fumarate) fumarate) OtherOther side side effects effects associated associated with with COMPLERA: COMPLERA: phenytoinphenytoin (Dilantin (Dilantin®®, Dilantin-125, Dilantin-125®®, Phenytek, Phenytek®®) ) • •have have bone bone problems problems combinedcombined in in one one pill. pill. COMPLERA COMPLERA is is used used as as a acomplete complete single-tablet single-tablet regimen regimen to to treat treat • • vomiting, vomiting, stomach stomach pain pain or or discomfort, discomfort, skin skin discoloration discoloration (small (small spots spots or or freckles), freckles), • • ®® • • are are It It is is not not known known if if COMPLERA COMPLERA can can harm harm the the anti-tuberculosis anti-tuberculosis medicines medicines rifabutin rifabutin (Mycobutin), (Mycobutin), rifampin rifampin (Rifater (Rifater, , pregnantpregnant or or plan plan to to become become pregnant. pregnant. andand pain pain HIVHIV-1-1 infection infection in in adults adults (age (age 18 18 and and older) older) who who have have never never taken taken HIV HIV medicines medicines before. before. RifamateRifamate®®, Rimactane, Rimactane®®, Rifadin, Rifadin®®) )and and rifapentine rifapentine (Priftin (Priftin®®) ) youryour unborn unborn child child COMPLERACOMPLERA does does not not cure cure HIV HIV and and has has not not been been shown shown to to prevent prevent pa passingssing HIV HIV • • a aproton proton pump pump inhibitor inhibitor medicine medicine for for certain certain stomach stomach or or intestinal intestinal problems, problems, • • are are breastfeeding; breastfeeding; women women with with HIV HIV should should not not breast-feed breast-feed because because they they can can pass pass TellTell your your healthcare healthcare provider provider if if you you have have any any side side effect effect that that bothers bothers you you or or that that toto others. others. It It is is important important to to always always practice practice safer safer sex, sex, use use latex latex or or polyurethane polyurethane includingincluding esomeprazole esomeprazole (Nexium (Nexium®®, V, imovoVimovo®®),), lansoprazole lansoprazole (Prevacid (Prevacid®®),), HIVHIV through through their their milk milk to to the the baby baby doesdoes not not go go away away. These. These are are not not all all the the possible possible side side effects effects of of COMPLERA. COMPLERA. For For more more ®® ®® ®® information,information, ask ask your your healthcare healthcare provider provider or or pharmacist. pharmacist. Call Call your your healthcare healthcare provider provider condomscondoms to to lower lower the the chance chance of of sexual sexual contact contact with with any any body body fl fluids, uids, and and to to never never omeprazoleomeprazole (Prilosec (Prilosec),), pantoprazole pantoprazole sodium sodium (Protonix (Protonix),), rabeprazole rabeprazole (Aciphex (Aciphex) ) ContactContact your your healthcare healthcare provider provider right right away away if if you you experience experience a anyny of of the the • • forfor medical medical advice advice about about side side effects. effects. re-usere-use or or share share needles. needles. Do Do not not stop stop taking taking COMPLERA COMPLERA unless unless directed directed by by your your more more than than 1 1 dose dose of of the the steroid steroid medicine medicine dexamethasone dexamethasone or or dexamethasone dexamethasone followingfollowing serious serious or or common common side side effects: effects: healthcarehealthcare provider provider. See. See your your healthcare healthcare provider provider regularly regularly. sodiumsodium phosphate phosphate SeriousSerious side side effects effects associated associated with with COMPLERA: COMPLERA: YouYou are are encouraged encouraged to to report report negative negative side side effects effects of of prescripti prescriptionon drugs drugs to to the the • • St. St. John’ John’s swort wort (Hypericum (Hypericum perforatum) perforatum) • • New New or or worse worse kidney kidney problems problems can can happen happen in in some some people people who who take take COMPLERA. COMPLERA. FDA.FDA. Visit Visit www www.fda.gov/medwatch.fda.gov/medwatch or or call call 1-800-FDA-1088. 1-800-FDA-1088. • • other other medicines medicines that that contain contain tenofovir tenofovir (VIREAD (VIREAD®®, TRUV, TRUVADAADA®®, A, TRIPLAATRIPLA®®) ) IfIf you you have have had had kidney kidney problems problems in in the the past past or or take take other other medicines medicines that that can can cause cause TakeTake COMPLERA COMPLERA exactly exactly as as your your healthcare healthcare provider provider tells tells you you to to t aketake it it IMPORTIMPORTANTANT SAFETY SAFETY INFORMA INFORMATIONTION • • other other medicines medicines that that contain contain emtricitabine emtricitabine or or lamivudine lamivudine (EMTRIV (EMTRIVAA®®, Combivir, Combivir®®, , kidneykidney problems, problems, your your healthcare healthcare provider provider may may need need to to do do blood blood tests tests to to check check your your • •Always Always take take COMPLERA COMPLERA with with a a meal. meal. T akingTaking COMPLERA COMPLERA with with a a meal meal is is important important to to ContactContact your your healthcare healthcare provider provider right right away away if if you you get get the the foll followingowing side side effects effects EpivirEpivir®® or or Epivir Epivir-HBV-HBV®®, Epzicom, Epzicom®®, T, rizivirTrizivir®®) ) kidneyskidneys during during your your treatment treatment with with COMPLERA COMPLERA helphelp get get the the right right amount amount of of medicine medicine in in your your body body. A. A protein protein drink drink does does not not replace replace oror conditions conditions while while taking taking COMPLERA: COMPLERA: • •rilpivirine rilpivirine (Edurant (Edurant™™) ) • •Depression Depression or or mood mood changes changes can can happen happen in in some some people people who who take take COMPLERA. COMPLERA. aa meal meal • • Nausea, Nausea, vomiting, vomiting, unusual unusual muscle muscle pain, pain, and/or and/or weakness. weakness. These These m mayay be be • •adefovir adefovir (HEPSERA (HEPSERA®®) ) TellTell your your healthcare healthcare provider provider right right away away if if you you have have any any of of the the following following symptoms: symptoms: • • Stay Stay under under the the care care of of your your healthcare healthcare provider provider during during treatmen treatment twith with signssigns of of a a buildup buildup of of acid acid in in the the blood blood (lactic (lactic acidosis), acidosis), whic whichh is is a a serious serious InIn addition, addition, also also tell tell your your healthcare healthcare provider provider if if you you take: take: feelingfeeling sad sad or or hopeless, hopeless, feeling feeling anxious anxious or or restless, restless, or or if if you you have have thoughts thoughts of of COMPLERACOMPLERA and and see see your your healthcare healthcare provider provider regularly regularly medicalmedical condition condition • • an an antacid antacid medicine medicine that that contains contains aluminum, aluminum, magnesium
Recommended publications
  • Altering Cell Death Pathways As an Approach to Cure HIV Infection

    Altering Cell Death Pathways As an Approach to Cure HIV Infection

    Citation: Cell Death and Disease (2013) 4, e718; doi:10.1038/cddis.2013.248 OPEN & 2013 Macmillan Publishers Limited All rights reserved 2041-4889/13 www.nature.com/cddis Review Altering cell death pathways as an approach to cure HIV infection AD Badley*,1,2, A Sainski2,3, F Wightman4,5 and SR Lewin4,5 Recent cases of successful control of human immunodeficiency virus (HIV) by bone marrow transplant in combination with suppressive antiretroviral therapy (ART) and very early initiation of ART have provided proof of concept that HIV infection might now be cured. Current efforts focusing on gene therapy, boosting HIV-specific immunity, reducing inflammation and activation of latency have all been the subject of recent excellent reviews. We now propose an additional avenue of research towards a cure for HIV: targeting HIV apoptosis regulatory pathways. The central enigma of HIV disease is that HIV infection kills most of the CD4 T cells that it infects, but those cells that are spared subsequently become a latent reservoir for HIV against which current medications are ineffective. We propose that if strategies could be devised which would favor the death of all cells which HIV infects, or if all latently infected cells that release HIV would succumb to viral-induced cytotoxicity, then these approaches combined with effective ART to prevent spreading infection, would together result in a cure for HIV. This premise is supported by observations in other viral systems where the relationship between productive infection, apoptosis resistance, and the development of latency or persistence has been established. Therefore we propose that research focused at understanding the mechanisms by which HIV induces apoptosis of infected cells, and ways that some cells escape the pro-apoptotic effects of productive HIV infection are critical to devising novel and rational approaches to cure HIV infection.
  • The Importance of Community Engagement in Hiv Cure Research

    The Importance of Community Engagement in Hiv Cure Research

    tagline Vol. 26, No. 1, May 2019 SCIENTIFIC COMPLEXITY AND ETHICAL UNCERTAINTIES: THE IMPORTANCE OF COMMUNITY ENGAGEMENT IN HIV CURE RESEARCH By Richard Jefferys Introduction The past decade has seen a major expansion of the research Recent presentations at the March 2019 CROI indicate that effort to develop a cure for HIV infection. The U.S. National two additional people may have joined Brown,6,7 but follow-up Institutes of Health (NIH), the world’s largest biomedical is far shorter: One of the individuals has been off ART without research funder, has identified the pursuit of a cure as one of evidence of HIV rebound for 18 months, while the other is at five primary priorities for HIV.1 Total global financial support about four months. increased substantially in the period 2012–2017, from $88 million to $288.8 million.2 In 2014, TAG launched an online Translating to a Wider Community listing of cure-related clinical research drawn from registries (primarily ClinicalTrials.gov). The list initially contained less These additional cases of possible cures are encouraging, than 50 entries; it currently includes 98 clinical trials and 34 but the method used to achieve this outcome cannot be observational studies that are ongoing.3 Over 7,000 people used in most people with HIV, who do not require stem cell are expected to enroll in these studies. transplants for cancer (the high mortality risk associated with transplantation precludes its use outside of this setting). As with other areas of HIV research, engagement of the community of people living with HIV and their advocates is In the absence of any known safe alternatives for obtaining vital for ensuring that the conduct of cure-related studies is similarly robust depletion of HIV from the body, investigators ethical, appropriate, and responsive to community priorities.
  • Defining Clinical Issues Around Tolerance, Hyperalgesia, And

    Defining Clinical Issues Around Tolerance, Hyperalgesia, And

    ORIGINAL ARTICLE Defining clinical issues around tolerance, hyperalgesia, and addiction: A quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice Jennifer P. Schneider, MD, PhD; Kenneth L. Kirsh, PhD ARTICLE INFO ABSTRACT Keywords: Treatment with opioid medications has grown over the past decades, but has been tolerance surrounded by some ongoing controversy and debate to whether it is causing more dependence opioids harm than good for patients. To this end, the field of pain management has suf- hyperalgesia fered from a lack of clarity about some basic definitions on concepts such as toler- long-term opioid therapy ance and hyperalgesia. Some characterize these issues as inevitable parts of opioid therapy while other schools of thought look at these issues as relatively rare occur- Article history: rences. Unfortunately, most of the rhetoric around these topics has occurred with Received 13 February 2010 very little in the realm of real world data. To this end, the authors have reviewed Received in revised form 26 July 2010; the charts of 197 patients treated by a pain specialist for at least 1 year to better 30 August 2010 Accepted 31 August 2010 illustrate whether notions of tolerance and hyperalgesia are common occurrences DOI:10.5055/jom.2010.0036 and, more importantly, whether they occur within any type of specified timeframe. A total of 197 patient charts were reviewed. The sample had an average age of 49.39 years (range ϭ 19-87 years; standard deviation [SD] ϭ 12.48) and com- prised 66 men (33.5 percent) and 131 women (66.5 percent).
  • G HIV/AIDS & Immune Evasion Strategies the Year 1981…

    G HIV/AIDS & Immune Evasion Strategies the Year 1981…

    Micro 320: Infectious Disease & Defense HIV/AIDS & Immune Evasion Strategiesg Wilmore Webley Dept. of Microbiology The Year 1981… Reported by MS Gottlieb, MD, HM Schanker, MD, PT Fan, MD, A Saxon, MD, JD Weisman, DO, Div of Clinical Immunology-Allergy; Dept of Medicine, UCLA School of Medicine; I Pozalski, MD, Cedars-Mt. Siani Hospital, Los Angeles; Field services Div, Epidemiology Program Office, CDC. First Encounter: Dr. Michael Gottleib http://www.pbs.org/wgbh/pages/frontline/aids/view/ What is AIDS? Acquired Immune Deficiency Syndrome • Acquired means you can get infected with it (not inherited) • Immune Deficiency means a weakness in the body's system that fights diseases. • Syndrome means a group of health problems that make up a disease. The term AIDS refers to an advanced stage of HIV infection, when the immune system has sustained substantial damage. Not everyone who has HIV infection develops AIDS http://www.pbs.org/wgbh/pages/fro ntline/aids/view/ Global Statics of HIV/AIDS Transmission of HIV “Patient Zero” and HIV Transmission Gaëtan Dugas: A Canadian who worked for Air Canada as a flight attendant Claimed to have had over 2,500 sexual partners across North America 1972 Diagnosed with Kaposi's Sarcoma in June 1980 In 1982 the CDC linked him to 9 of the first 19 cases in Los Born February 20, 1953 Angeles, 22 cases in NYC and 9 March 30, 1984 Died (aged 31) more in 8 other cities – Total of 40 Quebec City, Quebec of the first 248 cases in the U.S. Occupation Flight attendant New Model: HIV Traveled to Haiti, Then U.S.
  • Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics

    Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics

    December 6, 2000 NIDA-CTN-0007 MOTIVATIONAL INCENTIVES FOR ENHANCED DRUG ABUSE RECOVERY: METHADONE CLINICS Maxine Stitzer, Ph.D., Lead Investigator Nancy Petry, Ph.D. Co-Lead Investigator Robert Brooner, Ph.D. Co-Investigator Jessica Peirce, Project Coordinator Protocol work group: Nancy Petry New England Paul McLaughlin New England Richard Rawson Pacific Frank Flammino Pacific Bob Forman Delaware Valley Peter Barbur Northwest Sara Lamb Northwest Scott Kellogg New York Elaine Pencer New York Jack Blaine NIDA NIDA-CTN-0007 Motivational Incentives: Methadone Clinic 1 Version 6, Date December 6, 2000 December 6, 2000 TABLE OF CONTENTS 1 LIST OF ABBREVIATIONS................................................................................................. 3 2 PROTOCOL SUMMARY...................................................................................................... 4 3 BACKGROUND AND SIGNIFICANCE.............................................................................. 7 4 STUDY OBJECTIVE........................................................................................................... 10 5 SUSTAINABILITY WITHIN THE CTP’S ........................................................................ 10 6 STUDY DESIGN.................................................................................................................. 11 6.1 Drug targets....................................................................................................................... 11 6.2 Bonus incentive targets: opiates.......................................................................................
  • Collision of COVID-19 on Opioid Overdose and Treatment

    Collision of COVID-19 on Opioid Overdose and Treatment

    Emerging Issues in the Opioid Crisis Nora D. Volkow, M.D. Director National Institute on Drug Abuse @NIDAnews Overdose Deaths in 2019 Increased by 4.6% Number of Deaths Number of Deaths 40,000 Fentanyl, 37,137 18,000 Prescription opioids, 14,347 Methamphetamine, 16,539 35,000 16,000 Heroin, 14,278 Cocaine, 16,196 30,000 14,000 12,000 25,000 10,000 20,000 8,000 15,000 6,000 10,000 4,000 5,000 2,000 0 0 Overdose Death Rates: Other Synthetic Narcotics (Including Illicit Fentanyl) 2013 2018 Source: CDC WONDER. Age-adjusted death rates per 100,000. Overdose Death Rates: Psychostimulants With Abuse Potential (Including Methamphetamine) 2013 2018 Source: CDC WONDER. Age-adjusted death rates per 100,000. Intersection Between Opioid Crisis and COVID-19 ` Overdoses Grew Dramatically During COVID Pandemic ST Drug Use Increase During COVID Total US Increase 31.96% 19.96% 10.06% 12.52% 7 Millennium Health Signals Report™ COVID-19 Special Edition: Significant Changes in Drug Use During the Pandemic Volume 2.1 | Published July 2020 Total Study Population Change in Unadjusted Positivity Rate for Cocaine, Fentanyl, Heroin and Methamphetamine COVID-Related Policy Changes for Prescribing Medications for OUD Methadone Buprenorphine Prior to COVID: Prior to COVID: • Only federally-approved opioid • Prescribed through pharmacies in outpatient treatment programs settings • In-person for daily dosing • DATA 2000, limited to clinicians with bup. waivers that required additional training and Under COVID, SAMSHA allowed: federal registration • 3/16/2020: 28 day
  • Appendix 1 – Data Code Values

    Appendix 1 – Data Code Values

    Florida Department of Children and Families Substance Abuse and Mental Health Financial and Services Accountability Management System (FASAMS) Pamphlet 155-2 Appendix 1 Data Code Values Last Revision Date: 10/01/2021 Effective Date: 7/01/2021 Version 14.0 Pamphlet 155-2 Appendix 1, Version 14.0 Last Revision Date 10/01/2021 Effective Date: 7/01/2021 Page 1 of 64 Table of Contents 1 State/Province ................................................................................................................................................................ 3 2 County Area .................................................................................................................................................................... 4 3 Covered Service .............................................................................................................................................................. 5 4 Service Category ............................................................................................................................................................. 9 5 Project Codes .................................................................................................................................................................. 9 6 Project Codes, Method of Payment and Unit of Measure ........................................................................................... 13 7 FY 2021-22 Active OCA Codes ......................................................................................................................................
  • Wisconsin Opioid Treatment Program Patient Reference Handbook

    Wisconsin Opioid Treatment Program Patient Reference Handbook

    WISCONSIN Opioid Treatment Program PATIENT REFERENCE HANDBOOK Department of Health Services Division of Care and Treatment Services Bureau of Prevention Treatment and Recovery P-23048 (09/2016) WELCOME Congratulations on taking the first step into treatment and long-term recovery from your addiction! At this point, you may be unsure of how treatment works and what to expect. This book is designed to provide you and your loved ones answers to questions you may have concerning treatment. Please note that this book is a reference tool to use. If you have questions after reading this handbook, please make sure to ask a staff person. The information that is provided in this handbook should be seen as guidelines for narcotic treatment clients. This handbook provides guidance of often difficult to understand state and federal regulations. Further, this guidance should not be construed as providing rigid answers, except in those areas where state or federal laws exist. Please refer to individual clinic policies and procedures if you have questions or are unsure of the rules when it comes to medication-assisted treatment. Life is very interesting...in the end, some of your greatest pains become your greatest strengths. Drew Barrymore Quote for Overcoming Addiction Wisconsin Department of Health Services Division of Care and Treatment Services Bureau of Prevention Treatment and Recovery State Opioid Treatment Authority 1 West Wilson Street Room 850 Madison WI 53703 October 2011 Revised September 2016 OPIOID TREATMENT SERVICE – PATIENT REFERENCE
  • Where's the Cure?

    Where's the Cure?

    A QUARTERLY JOURNAL ON HIV PREVENTION, TREATMENT AND POLITICS VOLUME 5, NO. 3 acHIeVe INSIDE Personal Perspective: CHANGING MY GENES 6 Where’s Being part of something as big as the search for the cure is a humbling experience. INCHING The TOWARD A VACCINE 9 The past two years Cure? have seen discover- ies that give hope that it may be possible to find an effective vaccine. THE FUTURE OF HIV PREVENTION 12 Three decades into the HIV epidemic, the A Look At Research number of new infections remains distress- ingly high. Across the U.S. HEPATITIS C: NEW DANGERS, that NIH granting procedures drastically NEW HOPES 16 by Stephen LeBlanc New information on slowed research and diverted money to transmission and a cure. university overhead costs, rather than to n 2009, Martin Delaney, a leading the search for a cure. Proponents esti- AIDS activist and the founder of Personal Perspective: mated a budget for the AIDS Cure Project Project Inform, co-authored an arti- MY FIGHT FOR A of $1.84 billion over five years. cle in Science calling for a new “HIV HEPATITIS C CURE 20 ICollaboratory” to focus on cure research. The Delaney Collaboratories The data on the new drug looked fabulous. The Collaboratory would be designed “to Nothing like the HIV Collaboratory or I thought, “I want this drug!” accelerate basic discovery and the clinical the AIDS Cure Project ever emerged, LOOKING BACK, translation of these discoveries.” Sadly, either in the amount of funding or in the LOOKING FOR- he died before the article was published.
  • Treatment of Co-Occurring Chronic Pain and Opioid Use Disorder

    Treatment of Co-Occurring Chronic Pain and Opioid Use Disorder

    YALE UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF PSYCHIATRY DIVISION OF SUBSTANCE ABUSE Treatment of co-occurring chronic pain and opioid use disorder Declan T. Barry, Ph.D. No conflicts of interest to report Aims of Today’s Talk Co-occurring chronic pain and opioid use disorder • Experiences of patients and providers • Potentially useful treatment approaches Chronic Pain: Prevalence and Burden Cross-national estimates of chronic pain: 1 • 10% in general population 2 • 20% in primary care Institute of Medicine Report • About 100 million adults • Annual societal costs: $560-635 billion3 Low back pain: 6th leading cause of disease burden 4 • 1206 disability-adjusted life years per 100,000 1. Verhaak, PF, Kerssens, JJ, Dekker, J, Sorbi, MJ, Bensing, JM. Prevalence of chronic benign pain disorder among adults: A review of the literature. Pain. 1998;77:231-239. 2. Gureje, O, Simon, GE, Von Korff, M. A cross-national study of the course of persistent pain in primary care. Pain. 2001;92:195-200. 3. Institute of Medicine. Relieving pain in America. 2011. 4. Murray et al. Disability-adjusted years. Lancet. 2012; 380: 2197-223 Veterans and Pain Pain prevalence • Higher than the general population • Up to 50% of men1 • 75% of women2 Frequent presenting complaint at Veterans Health Administration (VHA)3 Prevalence of low back pain in Veterans is growing4 1. Kerns et al. Veterans’ reports of pain and associations with ratings of health, health risk behaviors, affective distress, and use of the healthcare system. J Rehabil Res Dev. 2003;40:371-380. 2. Haskell et al. The prevalence of painful musculoskeletal conditions in female and male veterans.
  • Experiences of Opioid Detoxification

    Experiences of Opioid Detoxification

    Experiences of opioid detoxification using ibogaine in various treatment settings: Exploring ibogaine users’ motivations, understanding of risks, and effects of ibogaine treatment A thesis submitted for the degree of Masters of Health Sciences University of Otago, Christchurch New Zealand Jamie Walker December 2016 ABSTRACT Introduction Opioid dependence is a significant health concern in New Zealand. It has been estimated that there are 10,000 people who are daily or almost daily intravenous users of opioid drugs, half of whom are receiving opioid substitution treatment (OST) Similar to overseas countries. It is also estimated that there is a growing number of people in New Zealand who are dependent on prescribed opioids. However how many is currently unknown (Adamson et al., 2012). One alternative intervention for opioid dependence is ibogaine treatment. Ibogaine is a hallucinogenic drug that alleviates opioid withdrawal symptoms for up to three months. (Alper, Lotsof, Frenken, Luciano, & Bastiaans, 1999). However, ibogaine's metabolites interfere with cardiac centres in the brain, in some cases causing heart arrhythmia and death (Maas & Strubelt, 2006). Ibogaine providers promote pre-treatment tests (bloods and electrocardiogram (ECG)) reducing this risk (Alper, Lotsof, & Kaplan, 2008). Anecdotal reports suggest ibogaine treatments can occur with support from ibogaine treatment providers, ranging to; ‘peer to peer’ use with unknown medical advice. The aim of this study was to explore the experiences of people who had used ibogaine in New Zealand; and to discover what, or if, any medical tests had been sought and/or accessed. Method A qualitative, collective case-study research design was used. Ten people who used ibogaine for their opioid detoxification were recruited.
  • 2016 Annual Report

    2016 Annual Report

    June 12, 2017 Dear Friend of TAG: I’m so proud to share with you Treatment Action Group’s 2016 Annual Report. As you will see, TAG’s passionately dedicated, deeply informed staff have been unstinting in their efforts to speed up research and high-quality prevention, treatment, and care programs for people living with HIV, hepatitis C virus (HCV), or tuberculosis (TB), and for those most at risk of acquiring these infections. Today, more than ever, TAG’s work is vital. We are living Ending the in an unprecedented political era. Every day brings a new outrage and gathering threats to our work promoting research, prevention, and treatment. Everything TAG has fought for over the past three decades to defeat HIV/AIDS and end the TB and HCV Epidemic epidemics is at risk. Our progress towards ending these epidemics with Progress in the Fight extremely effective new tools for prevention, treatment, and cures will be in vain if people don’t have comprehensive for Better Treatment, coverage to ensure access. TAG’s vital work needs your support now more than ever: a Vaccine, and a • TAG is leading community efforts to end AIDS as an 2016 epidemic in New York State by the close of 2020 by Cure for AIDS Annual strengthening HIV, STD, and sexual health programs for Report those most affected • TAG is expanding its Ending the Epidemic work to southern states where the HIV/AIDS epidemic continues at its worst • TAG is leading efforts to build on existing law and regulation to control drug costs • TAG is leading efforts to defend key National Institutes of Health AIDS research agencies and their budgets from brutal cuts proposed by the new administration • TAG is fighting efforts to greatly weaken the U.S.